Rubbert-Roth A - Search Results

1

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. Smolen JS, et al. Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25. Ann Rheum Dis. 2014. PMID: 24161836 Free PMC article.

2

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators. Smolen JS, et al. Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5. Lancet. 2008. PMID: 18358926 Clinical Trial.

3

[Recommendations on the use of rituximab for patients with rheumatoid arthritis].

Rubbert-Roth A, Burmester G; Kommission Pharmakotherapie der DGRh. Rubbert-Roth A, et al. Z Rheumatol. 2008 Nov;67(7):609-13. doi: 10.1007/s00393-008-0348-8. Z Rheumatol. 2008. PMID: 18830700 German. No abstract available.

4

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.

Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM; IMAGE Investigators. Tak PP, et al. Ann Rheum Dis. 2011 Jan;70(1):39-46. doi: 10.1136/ard.2010.137703. Epub 2010 Oct 11. Ann Rheum Dis. 2011. PMID: 20937671 Clinical Trial.

5

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Burmester GR, et al. Ann Rheum Dis. 2011 May;70(5):755-9. doi: 10.1136/ard.2010.139725. Epub 2010 Dec 27. Ann Rheum Dis. 2011. PMID: 21187298 Free PMC article. Clinical Trial.

6

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.

Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Müller-Ladner U, Gaylis NB, Williams S, Reynard M, Tyrrell H. Emery P, et al. Rheumatology (Oxford). 2011 Dec;50(12):2223-32. doi: 10.1093/rheumatology/ker253. Epub 2011 Sep 16. Rheumatology (Oxford). 2011. PMID: 21926153 Free PMC article. Clinical Trial.

7

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.

Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T. Tak PP, et al. Ann Rheum Dis. 2012 Mar;71(3):351-7. doi: 10.1136/annrheumdis-2011-200170. Epub 2011 Oct 19. Ann Rheum Dis. 2012. PMID: 22012969 Free PMC article. Clinical Trial.

8

To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50.

Buch MH, Rubbert-Roth A, Ferraccioli G. Buch MH, et al. Autoimmun Rev. 2012 Jun;11(8):558-62. doi: 10.1016/j.autrev.2011.10.012. Epub 2011 Oct 22. Autoimmun Rev. 2012. PMID: 22037117 Review.

9

Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.

Pavelka K, Kavanaugh AF, Rubbert-Roth A, Ferraccioli G. Pavelka K, et al. Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v12-21. doi: 10.1093/rheumatology/kes111. Rheumatology (Oxford). 2012. PMID: 22718922 Review.

10

[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Krüger K, Wollenhaupt J, Albrecht K, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester G, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U; European League of Associations for Rheumatology (EULAR). Krüger K, et al. Z Rheumatol. 2012 Sep;71(7):592-603. doi: 10.1007/s00393-012-1038-0. Z Rheumatol. 2012. PMID: 22930110 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters